APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hypereosinophilic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hypereosinophilic Syndrome Drug Market Outlook and Growth Opportunities 2026

19 December 2025196 pages

Choose your research edition.

Industry ResearchHypereosinophilic Syndrome Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hypereosinophilic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hypereosinophilic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hypereosinophilic Syndrome Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hypereosinophilic Syndrome Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hypereosinophilic Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hypereosinophilic Syndrome Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hypereosinophilic Syndrome Drug market include GlaxoSmithKline Plc, Stemline Therapeutics Inc, Kyowa Hakko Kirin Co Ltd, Knopp Biosciences LLC and Bristol-Myers Squibb Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hypereosinophilic Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hypereosinophilic Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hypereosinophilic Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hypereosinophilic Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hypereosinophilic Syndrome Drug Segment by Company

GlaxoSmithKline Plc

Stemline Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Knopp Biosciences LLC

Bristol-Myers Squibb Co

Hypereosinophilic Syndrome Drug Segment by Type

Dexpramipexole Dihydrochloride

Mepolizumab

Dasatinib

Benralizumab

Others

Hypereosinophilic Syndrome Drug Segment by Application

Clinic

Hospital

Research Center

Hypereosinophilic Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Hypereosinophilic Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hypereosinophilic Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hypereosinophilic Syndrome Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Hypereosinophilic Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypereosinophilic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hypereosinophilic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypereosinophilic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hypereosinophilic Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hypereosinophilic Syndrome Drug industry.

Chapter 3: Detailed analysis of Hypereosinophilic Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hypereosinophilic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hypereosinophilic Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hypereosinophilic Syndrome Drug Industry Trends Table 2. Hypereosinophilic Syndrome Drug Industry Drivers Table 3. Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges Table 4. Hypereosinophilic Syndrome Drug Industry Restraints Table 5. Global Hypereosinophilic Syndrome Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hypereosinophilic Syndrome Drug Revenue Share by Company (2021-2026) Table 7. Global Hypereosinophilic Syndrome Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Company (2021-2026) Table 9. Global Hypereosinophilic Syndrome Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Hypereosinophilic Syndrome Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hypereosinophilic Syndrome Drug Key Company Manufacturing Base & Headquarters Table 12. Global Hypereosinophilic Syndrome Drug Company, Product Type & Application Table 13. Global Hypereosinophilic Syndrome Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hypereosinophilic Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Dexpramipexole Dihydrochloride Table 18. Significant Companies of Mepolizumab Table 19. Significant Companies of Dasatinib Table 20. Significant Companies of Benralizumab Table 21. Significant Companies of Others Table 22. Global Hypereosinophilic Syndrome Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Hypereosinophilic Syndrome Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Hypereosinophilic Syndrome Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Type (2021-2026) Table 26. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Type (2027-2032) Table 27. Global Hypereosinophilic Syndrome Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hypereosinophilic Syndrome Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Hypereosinophilic Syndrome Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Hypereosinophilic Syndrome Drug Sales Value Share by Type (2021-2026) Table 31. Global Hypereosinophilic Syndrome Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Research Center Table 35. Global Hypereosinophilic Syndrome Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Hypereosinophilic Syndrome Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Hypereosinophilic Syndrome Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Application (2021-2026) Table 39. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Application (2027-2032) Table 40. Global Hypereosinophilic Syndrome Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Hypereosinophilic Syndrome Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Hypereosinophilic Syndrome Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Hypereosinophilic Syndrome Drug Sales Value Share by Application (2021-2026) Table 44. Global Hypereosinophilic Syndrome Drug Sales Value Share by Application (2027-2032) Table 45. Global Hypereosinophilic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region (2021-2026) Table 48. Global Hypereosinophilic Syndrome Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region (2027-2032) Table 50. Global Hypereosinophilic Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Hypereosinophilic Syndrome Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Hypereosinophilic Syndrome Drug Sales Value Share by Region (2021-2026) Table 53. Global Hypereosinophilic Syndrome Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Hypereosinophilic Syndrome Drug Sales Value Share by Region (2027-2032) Table 55. Global Hypereosinophilic Syndrome Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Hypereosinophilic Syndrome Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Hypereosinophilic Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2026) Table 61. Global Hypereosinophilic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Hypereosinophilic Syndrome Drug Sales Market Share by Country (2027-2032) Table 63. Global Hypereosinophilic Syndrome Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Hypereosinophilic Syndrome Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Hypereosinophilic Syndrome Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Hypereosinophilic Syndrome Drug Sales Value Market Share by Country (2027-2032) Table 67. GlaxoSmithKline Plc Company Information Table 68. GlaxoSmithKline Plc Business Overview Table 69. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio Table 71. GlaxoSmithKline Plc Recent Development Table 72. Stemline Therapeutics Inc Company Information Table 73. Stemline Therapeutics Inc Business Overview Table 74. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio Table 76. Stemline Therapeutics Inc Recent Development Table 77. Kyowa Hakko Kirin Co Ltd Company Information Table 78. Kyowa Hakko Kirin Co Ltd Business Overview Table 79. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio Table 81. Kyowa Hakko Kirin Co Ltd Recent Development Table 82. Knopp Biosciences LLC Company Information Table 83. Knopp Biosciences LLC Business Overview Table 84. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio Table 86. Knopp Biosciences LLC Recent Development Table 87. Bristol-Myers Squibb Co Company Information Table 88. Bristol-Myers Squibb Co Business Overview Table 89. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio Table 91. Bristol-Myers Squibb Co Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Hypereosinophilic Syndrome Drug Distributors List Table 95. Hypereosinophilic Syndrome Drug Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Hypereosinophilic Syndrome Drug Product Image Figure 2. Global Hypereosinophilic Syndrome Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hypereosinophilic Syndrome Drug Sales (2021-2032) & (K Units) Figure 5. Global Hypereosinophilic Syndrome Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Hypereosinophilic Syndrome Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Dexpramipexole Dihydrochloride Image Figure 10. Mepolizumab Image Figure 11. Dasatinib Image Figure 12. Benralizumab Image Figure 13. Others Image Figure 14. Global Hypereosinophilic Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Hypereosinophilic Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Hypereosinophilic Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hypereosinophilic Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hypereosinophilic Syndrome Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Research Center Image Figure 23. Global Hypereosinophilic Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Hypereosinophilic Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Hypereosinophilic Syndrome Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Hypereosinophilic Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Hypereosinophilic Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Hypereosinophilic Syndrome Drug Sales Value Share by Application (2021-2032) Figure 29. Global Hypereosinophilic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Hypereosinophilic Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Hypereosinophilic Syndrome Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Hypereosinophilic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Hypereosinophilic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Hypereosinophilic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Hypereosinophilic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Hypereosinophilic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Hypereosinophilic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Hypereosinophilic Syndrome Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Hypereosinophilic Syndrome Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Dexpramipexole Dihydrochloride
  • Mepolizumab
  • Dasatinib
  • Benralizumab
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
Companies covered
  • GlaxoSmithKline Plc
  • Stemline Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Knopp Biosciences LLC
  • Bristol-Myers Squibb Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  4. 1.2.2 Global Hypereosinophilic Syndrome Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Hypereosinophilic Syndrome Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hypereosinophilic Syndrome Drug Market Dynamics
  1. 2.1 Hypereosinophilic Syndrome Drug Industry Trends
  2. 2.2 Hypereosinophilic Syndrome Drug Industry Drivers
  3. 2.3 Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Hypereosinophilic Syndrome Drug Industry Restraints
3 Hypereosinophilic Syndrome Drug Market by Company
  1. 3.1 Global Hypereosinophilic Syndrome Drug Company Revenue Ranking in 2025
  2. 3.2 Global Hypereosinophilic Syndrome Drug Revenue by Company (2021-2026)
  3. 3.3 Global Hypereosinophilic Syndrome Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Hypereosinophilic Syndrome Drug Average Price by Company (2021-2026)
  5. 3.5 Global Hypereosinophilic Syndrome Drug Company Ranking (2024-2026)
  6. 3.6 Global Hypereosinophilic Syndrome Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Hypereosinophilic Syndrome Drug Company Product Type and Application
  8. 3.8 Global Hypereosinophilic Syndrome Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hypereosinophilic Syndrome Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hypereosinophilic Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hypereosinophilic Syndrome Drug Market by Type
  1. 4.1 Hypereosinophilic Syndrome Drug Type Introduction
  2. 4.1.1 Dexpramipexole Dihydrochloride
  3. 4.1.2 Mepolizumab
  4. 4.1.3 Dasatinib
  5. 4.1.4 Benralizumab
  6. 4.1.5 Others
  7. 4.2 Global Hypereosinophilic Syndrome Drug Sales Volume by Type
  8. 4.2.1 Global Hypereosinophilic Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hypereosinophilic Syndrome Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Hypereosinophilic Syndrome Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Hypereosinophilic Syndrome Drug Sales Value by Type
  12. 4.3.1 Global Hypereosinophilic Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hypereosinophilic Syndrome Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Hypereosinophilic Syndrome Drug Sales Value Share by Type (2021-2032)
5 Hypereosinophilic Syndrome Drug Market by Application
  1. 5.1 Hypereosinophilic Syndrome Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.2 Global Hypereosinophilic Syndrome Drug Sales Volume by Application
  6. 5.2.1 Global Hypereosinophilic Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hypereosinophilic Syndrome Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hypereosinophilic Syndrome Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hypereosinophilic Syndrome Drug Sales Value by Application
  10. 5.3.1 Global Hypereosinophilic Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hypereosinophilic Syndrome Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hypereosinophilic Syndrome Drug Sales Value Share by Application (2021-2032)
6 Hypereosinophilic Syndrome Drug Regional Sales and Value Analysis
  1. 6.1 Global Hypereosinophilic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hypereosinophilic Syndrome Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Hypereosinophilic Syndrome Drug Sales by Region (2027-2032)
  5. 6.3 Global Hypereosinophilic Syndrome Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hypereosinophilic Syndrome Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hypereosinophilic Syndrome Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hypereosinophilic Syndrome Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Hypereosinophilic Syndrome Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  12. 6.6.2 North America Hypereosinophilic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Hypereosinophilic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hypereosinophilic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  21. 6.9.2 South America Hypereosinophilic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hypereosinophilic Syndrome Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hypereosinophilic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
7 Hypereosinophilic Syndrome Drug Country-level Sales and Value Analysis
  1. 7.1 Global Hypereosinophilic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hypereosinophilic Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hypereosinophilic Syndrome Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Hypereosinophilic Syndrome Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Hypereosinophilic Syndrome Drug Sales by Country (2027-2032)
  6. 7.4 Global Hypereosinophilic Syndrome Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hypereosinophilic Syndrome Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hypereosinophilic Syndrome Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hypereosinophilic Syndrome Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hypereosinophilic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hypereosinophilic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 Stemline Therapeutics Inc
  8. 8.2.1 Stemline Therapeutics Inc Company Information
  9. 8.2.2 Stemline Therapeutics Inc Business Overview
  10. 8.2.3 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio
  12. 8.2.5 Stemline Therapeutics Inc Recent Developments
  13. 8.3 Kyowa Hakko Kirin Co Ltd
  14. 8.3.1 Kyowa Hakko Kirin Co Ltd Company Information
  15. 8.3.2 Kyowa Hakko Kirin Co Ltd Business Overview
  16. 8.3.3 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio
  18. 8.3.5 Kyowa Hakko Kirin Co Ltd Recent Developments
  19. 8.4 Knopp Biosciences LLC
  20. 8.4.1 Knopp Biosciences LLC Company Information
  21. 8.4.2 Knopp Biosciences LLC Business Overview
  22. 8.4.3 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio
  24. 8.4.5 Knopp Biosciences LLC Recent Developments
  25. 8.5 Bristol-Myers Squibb Co
  26. 8.5.1 Bristol-Myers Squibb Co Company Information
  27. 8.5.2 Bristol-Myers Squibb Co Business Overview
  28. 8.5.3 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Co Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hypereosinophilic Syndrome Drug Value Chain Analysis
  2. 9.1.1 Hypereosinophilic Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hypereosinophilic Syndrome Drug Sales Mode & Process
  6. 9.2 Hypereosinophilic Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hypereosinophilic Syndrome Drug Distributors
  9. 9.2.3 Hypereosinophilic Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst